UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 SEC FILE NUMBER
1-13441
NOTIFICATION OF LATE FILING ---------------
CUSIP NUMBER
42366C103
---------------
(Check One):|_|Form 10-K |_|Form 20-F |_|Form 11-K |X| Form 10-Q |_|Form N-SAR
|_|Form N-CSR
For Period Ended: June 30,2006
-------------------
( ) Transition Report on Form 10-K
( ) Transition Report on Form 20-F
( ) Transition Report on Form 11-K
( ) Transition Report on Form 10-Q
( ) Transition Report on Form N-SAR
For the Transition Period Ended:_____________________________________
--------------------------------------------------------------------------------
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
--------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
--------------------------------------------------------------------------------
Full Name of Registrant
Hemispherx Biopharma, Inc.
--------------------------------------------------------------------------------
Former Name if Applicable
--------------------------------------------------------------------------------
Address of Principal Executive Offices (Street and Number)
1617 JFK Blvd. #660
--------------------------------------------------------------------------------
City, State and Zip Code
Philadelphia, PA 19103
--------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|X| (b) The subject quarterly report on Form 10-Q will be filed on or
before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12(b)-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why the Form 10-Q, or portion
thereof, could not be filed within the prescribed time period. (Attach Extra
Sheets If Needed)
The registrant was unable to file its form 10-Q for the period ended
June 30,2006 without unreasonable expense and effort due to its inability
to finish the form 10-Q within a sufficient time for management to review
the financial statements and complete the management discussion and analysis.
This quarterly report will be filed on or before the fifth calendar day
following the prescribed due date.
PART IV --OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Adam Pascale 215 988-0080
---------------------------------------------------------------------------
Name Area Code Telephone Number
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such reports been filed? If answer is no,
identify report(s). _ _
|x| Yes |_| No
---------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? _ _
|_| Yes |X| No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
----------------------------------------------
---------------------------------------------
--------------------------------------------------------------------------
Hemispherx Biopharma, Inc.
-------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on their behalf by the undersigned
hereunto duly authorized.
Date August 9, 2006 By /s/ William A. Carter
--------------------------- ---------------------------------------
William A. Carter, CEO
Instruction: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
-----------------------------------ATTENTION------------------------------------
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).
--------------------------------------------------------------------------------